Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates

–Phase 3 EMPEROR study of zorevunersen, an investigational medicine for Dravet syndrome: ~110 patients through Week 28 primary endpoint, ~20 patients through Week 52 and all continuing into open-label treatment period;